Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB has reported that the supplemental new drug application for the use of Neupro as adjunctive therapy with levodopa in adult patients with advanced-stage Parkinson's disease has been accepted for filing by the FDA.
Subscribe to our email newsletter
The sNDA is based on efficacy and safety data in more than 670 patients with advanced-stage Parkinson’s disease who were treated with rotigotine in three double-blind, placebo-controlled clinical trials. These studies demonstrated that rotigotine, as adjunctive therapy to levodopa in patients with advanced-stage Parkinson’s disease, showed clinically relevant reductions in ‘off’ time (periods where the effectiveness of medications wear off and Parkinson’s symptoms return) and favorable increases in ‘on’ time without troublesome dyskinesia (fragmented or jerky movements).
The FDA has already approved Neupro for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease and the drug has been commercially available in the United States since July 2007.
Troy Cox, president of CNS Operations, UCB, said: “We are excited that patients with all stages of Parkinson’s disease may soon benefit from Neupro’s 24-hour continuous drug delivery.”